Study of CM512 in Patients With Moderate-to-Severe Atopic Dermatitis
ConditionAtopic Dermatitis
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorKeymed Biosciences Co.Ltd
About this trial
A Phase 2 study designed to evaluate the efficacy and safety of CM512 in adult patients with moderate-to-severe Atopic Dermatitis (AD).
Eligibility criteria
Qualifiers
EASI≥16 at Screening and Baseline visits;
Investigator's Global Assessment (IGA) score of≥3 at Screening and Baseline visits;
10% Body Surface Area (BSA) of AD involvement at Screening and Baseline visits;
Mean of weekly Pruritus Numeric Rating Scale (NRS) severity score≥4 at Baseline;
Disqualifiers
Not enough washing-out period for previous therapy.
Concurrent disease/status which may potentially affect the efficacy/safety judgement.
Organ dysfunction.
Pregnancy.
Trial design
Treatments tested in this trial
- Placebo Comparator
- CM512
Treatment groups
200 Participants
are divided into 5 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov